UTHEALTH HOME ABOUT SBMI A-Z WEBMAIL INSIDE THE UNIVERSITY

Home

Download

Statistics

Examples

Help

Contact

	Kinase Fusion Gene Summary
	Kinase Fusion Gene Sample Information
	Kinase Fusion ORF Analysis
	Kinase Fusion Amino Acid Sequences
	Multiple Sequence Alignment of All Fusion Protein Isoforms
	Kinase Fusion Protein Functional Features
	Kinase Fusion Protein Structures
	Comparison of Fusion Protein Isoforms
	Comparison of Fusion Protein Sequences/Structures with Known Sequences/Structures from PDB
	pLDDT Scores and Difference Analysis of pLDDT Scores Between the Active Sites (Best) and Non-Active Sites.
	Ramachandran Plot of Kinase Fusion Protein Structure
	Potential Active Site Information
	Virtual Screening Results
	Kinase-Substrate Information
	Related Drugs with This Kinase Fusion Protein
	Related Disease with This Kinase Fusion Protein
	Clinical Trials of the Found Drugs/Small Molecules

Kinase Fusion Gene:XYLT1_ABR

Kinase Fusion Protein Summary

Kinase Fusion gene summary

Kinase Fusion partner gene information	Kinase Fusion gene name: XYLT1_ABR
	KinaseFusionDB ID: KFG7187
	FusionGDB2.0 ID: KFG7187
		Hgene	Tgene
	Gene symbol	XYLT1	ABR
	Gene ID	64131	29
	Gene name	xylosyltransferase 1	ABR activator of RhoGEF and GTPase
	Synonyms	DBQD2\|PXYLT1\|XT-I\|XT1\|XTI\|XYLTI\|xylT-I	MDB
	Cytomap	16p12.3	17p13.3
	Type of gene	protein-coding	protein-coding
	Description	xylosyltransferase 1beta-D-xylosyltransferase 1peptide O-xylosyltransferase 1xylosyltransferase Ixylosyltransferase iota	active breakpoint cluster region-related proteinABR, RhoGEF and GTPase activating proteinactive BCR-related
	Modification date	20240305	20240302
	UniProtAcc	Q86Y38	Q9P1F3
Ensembl transtripts involved in fusion gene	ENST ids	ENST00000261381, ENST00000568226,	ENST00000544583, ENST00000574437, ENST00000291107, ENST00000536794, ENST00000543210, ENST00000572441, ENST00000573895, ENST00000302538,
Context (manual curation of fusion genes in KinaseFusionDB)	PubMed: XYLT1 [Title/Abstract] AND ABR [Title/Abstract] AND fusion [Title/Abstract]
Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)	XYLT1(17352845)-ABR(1028702), # samples:1

Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez

Partner	Gene	GO ID	GO term	PubMed ID
Hgene	XYLT1	GO:0030166	proteoglycan biosynthetic process	11087729
Tgene	ABR	GO:0090630	activation of GTPase activity	7479768

Kinase Fusion gene breakpoints across XYLT1 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Kinase Fusion gene breakpoints across ABR (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.

Top

Kinase Fusion Gene Sample Information

Kinase Fusion gene information.

Kinase Fusion gene information from four resources (ChiTars 5.0, ChimerDB 4.0, COSMIC, and CCLE)
* All genome coordinats were lifted-over on hg19.
* Click on the break point to see the gene structure around the break point region using the UCSC Genome Browser.

Source	Sample	Hgene	Hchr	Hbp	Tgene	Tchr	Tbp
ChimerDB4	TCGA-IE-A4EJ-01A	XYLT1	chr16	17352845	ABR	chr17	1028702

Top

Kinase Fusion ORF Analysis

Kinase Fusion information from ORFfinder translation from full-length transcript sequence from KinaseFusionDB.

Henst	Tenst	Hgene	Hchr	Hbp	Tgene	Tchr	Tbp	Seq length (transcript)	Seq length (amino acids)
ENST00000261381	ENST00000302538	XYLT1	chr16	17352845	ABR	chr17	1028702	6079	1167

Top

Kinase Fusion Amino Acid Sequences

For individual full-length fusion transcript sequence from KinaseFusionDB, we ran ORFfinder and chose the longest ORF among the all predicted ones.

>Henst_Tenst_Hgene_Hchr_Hbp_Tgene_Tchr_Tbp_length(fusion AA)_AAseq

>ENST00000261381_ENST00000302538_XYLT1_chr16_17352845_ABR_chr17_1028702_length(amino acids)=1167
MRGARGRPGACRGPRASLAGRAPKMVAAPCARRLARRSHSALLAALTVLLLQTLVVWNFSSLDSGAGERRGGAAVGGGEQPPPAPAPRRE
RRDLPAEPAAARGGGGGGGGGGGGRGPQARARGGGPGEPRGQQPASRGALPARALDPHPSPLITLETQDGYFSHRPKEKVRTDSNNENSV
PKDFENVDNSNFAPRTQKQKHQPELAKKPPSRQKELLKRKLEQQEKGKGHTFPGKGPGEVLPPGDRAAANSSHGKDVSRPPHARKTGGSS
PETKYDQPPKCDISGKEAISALSRAKSKHCRQEIGETYCRHKLGLLMPEKVTRFCPLEDFSYGTDEYDGEGNEEQKGPPEGSETMPYIDE
SPTMSPQLSARSQGGGDGVSPTPPEGLAPGVEAGKGLEMRKLVLSGFLASEEIYINQLEALLLPMKPLKATATTSQPVLTIQQIETIFYK
IQDIYEIHKEFYDNLCPKVQQWDSQVTMGHLFQKLASQLGVYKAFVDNYKVALETAEKCSQSNNQFQKISEELKVKGPKDSKDSHTSVTM
EALLYKPIDRVTRSTLVLHDLLKHTPVDHPDYPLLQDALRISQNFLSSINEDIDPRRTAVTTPKGETRQLVKDGFLVEVSESSRKLRHVF
LFTDVLLCAKLKKTSAGKHQQYDCKWYIPLADLVFPSPEESEASPQVHPFPDHELEDMKMKISALKSEIQKEKANKGQSRAIERLKKKMF
ENEFLLLLNSPTIPFRIHNRNGKSYLFLLSSDYERSEWREAIQKLQKKDLQAFVLSSVELQVLTGSCFKLRTVHNIPVTSNKDDDESPGL
YGFLHVIVHSAKGFKQSANLYCTLEVDSFGYFVSKAKTRVFRDTAEPKWDEEFEIELEGSQSLRILCYEKCYDKTKVNKDNNEIVDKIMG
KGQIQLDPQTVETKNWHTDVIEMNGIKVEFSMKFTSRDMSLKRTPSKKQTGVFGVKISVVTKRERSKVPYIVRQCVEEVEKRGIEEVGIY
RISGVATDIQALKAVFDANNKDILLMLSDMDINAIAGTLKLYFRELPEPLLTDRLYPAFMEGIALSDPAAKENCMMHLLRSLPDPNLITF

--------------------------------------------------------------

Multiple Sequence Alignment of All Fusion Protein Isoforms

Top

Kinase Fusion Protein Functional Features

Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr16:17352845/chr17:1028702)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.

Main function of each fusion partner protein. (from UniProt)

Hgene	Tgene
XYLT1 Q86Y38	ABR Q9P1F3
FUNCTION: Catalyzes the first step in the biosynthesis of chondroitin sulfate and dermatan sulfate proteoglycans, such as DCN. Transfers D-xylose from UDP-D-xylose to specific serine residues of the core protein (PubMed:15461586, PubMed:17189265, PubMed:24581741, PubMed:23982343). Required for normal embryonic and postnatal skeleton development, especially of the long bones (PubMed:24581741, PubMed:23982343). Required for normal maturation of chondrocytes during bone development, and normal onset of ossification (By similarity). {ECO:0000250\|UniProtKB:Q811B1, ECO:0000269\|PubMed:15461586, ECO:0000269\|PubMed:17189265, ECO:0000269\|PubMed:23982343, ECO:0000269\|PubMed:24581741}.

Retention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, because of limited space for viewing, we only show the protein feature retention information belong to the 13 regional features. All retention annotation result can be downloaded at
download page
* Minus value of BPloci means that the break pointn is located before the CDS.

- Retained domain in the 5'-partner of fusion protein (protein functional feature from UniProt).

Partner

Hgeneene

Hbp

Tgeneene

Tbp

ENST

BPexon

TotalExon

Protein feature loci

BPloci

TotalLen

Feature

Note

- Retained domain in the 3'-partner of fusion protein (protein functional feature from UniProt).

Partner	Hgeneene	Hbp	Tgeneene	Tbp	ENST	BPexon	TotalExon	Protein feature loci	BPloci	TotalLen	Feature	Note
Tgene	XYLT1	17352845	ABR	1028702	ENST00000261381	0	22	484_613	0	814	Domain	Note=C2;Ontology_term=ECO:0000255;evidence=ECO:0000255\|PROSITE-ProRule:PRU00041
Tgene	XYLT1	17352845	ABR	1028702	ENST00000261381	0	22	484_613	0	823	Domain	Note=C2;Ontology_term=ECO:0000255;evidence=ECO:0000255\|PROSITE-ProRule:PRU00041
Tgene	XYLT1	17352845	ABR	1028702	ENST00000261381	0	23	484_613	0	814	Domain	Note=C2;Ontology_term=ECO:0000255;evidence=ECO:0000255\|PROSITE-ProRule:PRU00041
Tgene	XYLT1	17352845	ABR	1028702	ENST00000261381	0	23	484_613	20	860	Domain	Note=C2;Ontology_term=ECO:0000255;evidence=ECO:0000255\|PROSITE-ProRule:PRU00041
Tgene	XYLT1	17352845	ABR	1028702	ENST00000261381	0	8	484_613	0	311	Domain	Note=C2;Ontology_term=ECO:0000255;evidence=ECO:0000255\|PROSITE-ProRule:PRU00041
Tgene	XYLT1	17352845	ABR	1028702	ENST00000261381	0	22	91_284	0	814	Domain	Note=DH;Ontology_term=ECO:0000255;evidence=ECO:0000255\|PROSITE-ProRule:PRU00062
Tgene	XYLT1	17352845	ABR	1028702	ENST00000261381	0	22	91_284	0	823	Domain	Note=DH;Ontology_term=ECO:0000255;evidence=ECO:0000255\|PROSITE-ProRule:PRU00062
Tgene	XYLT1	17352845	ABR	1028702	ENST00000261381	0	23	91_284	0	814	Domain	Note=DH;Ontology_term=ECO:0000255;evidence=ECO:0000255\|PROSITE-ProRule:PRU00062
Tgene	XYLT1	17352845	ABR	1028702	ENST00000261381	0	23	91_284	20	860	Domain	Note=DH;Ontology_term=ECO:0000255;evidence=ECO:0000255\|PROSITE-ProRule:PRU00062
Tgene	XYLT1	17352845	ABR	1028702	ENST00000261381	0	8	91_284	0	311	Domain	Note=DH;Ontology_term=ECO:0000255;evidence=ECO:0000255\|PROSITE-ProRule:PRU00062
Tgene	XYLT1	17352845	ABR	1028702	ENST00000261381	0	22	301_459	0	814	Domain	Note=PH;Ontology_term=ECO:0000255;evidence=ECO:0000255\|PROSITE-ProRule:PRU00145
Tgene	XYLT1	17352845	ABR	1028702	ENST00000261381	0	22	301_459	0	823	Domain	Note=PH;Ontology_term=ECO:0000255;evidence=ECO:0000255\|PROSITE-ProRule:PRU00145
Tgene	XYLT1	17352845	ABR	1028702	ENST00000261381	0	23	301_459	0	814	Domain	Note=PH;Ontology_term=ECO:0000255;evidence=ECO:0000255\|PROSITE-ProRule:PRU00145
Tgene	XYLT1	17352845	ABR	1028702	ENST00000261381	0	23	301_459	20	860	Domain	Note=PH;Ontology_term=ECO:0000255;evidence=ECO:0000255\|PROSITE-ProRule:PRU00145
Tgene	XYLT1	17352845	ABR	1028702	ENST00000261381	0	8	301_459	0	311	Domain	Note=PH;Ontology_term=ECO:0000255;evidence=ECO:0000255\|PROSITE-ProRule:PRU00145
Tgene	XYLT1	17352845	ABR	1028702	ENST00000261381	0	22	647_845	0	814	Domain	Note=Rho-GAP;Ontology_term=ECO:0000255;evidence=ECO:0000255\|PROSITE-ProRule:PRU00172
Tgene	XYLT1	17352845	ABR	1028702	ENST00000261381	0	22	647_845	0	823	Domain	Note=Rho-GAP;Ontology_term=ECO:0000255;evidence=ECO:0000255\|PROSITE-ProRule:PRU00172
Tgene	XYLT1	17352845	ABR	1028702	ENST00000261381	0	23	647_845	0	814	Domain	Note=Rho-GAP;Ontology_term=ECO:0000255;evidence=ECO:0000255\|PROSITE-ProRule:PRU00172
Tgene	XYLT1	17352845	ABR	1028702	ENST00000261381	0	23	647_845	20	860	Domain	Note=Rho-GAP;Ontology_term=ECO:0000255;evidence=ECO:0000255\|PROSITE-ProRule:PRU00172
Tgene	XYLT1	17352845	ABR	1028702	ENST00000261381	0	8	647_845	0	311	Domain	Note=Rho-GAP;Ontology_term=ECO:0000255;evidence=ECO:0000255\|PROSITE-ProRule:PRU00172

Top

Kinase Fusion Protein Structures

CIF files of the predicted kinase fusion proteins
* Here we show the 3D structure of the fusion proteins using Mol*. AlphaFold produces a per-residue confidence score (pLDDT) between 0 and 100. Model confidence is shown from the pLDDT values per residue. pLDDT corresponds to the model’s prediction of its score on the local Distance Difference Test. It is a measure of local accuracy (from AlphfaFold website). To color code individual residues, we transformed individual PDB files into CIF format.

Kinase Fusion protein CIF link (fusion AA seq ID in KinaseFusionDB)	Henst	Tenst	Hgene	Hchr	Hbp	Tgene	Tchr	Tbp	AA seq	Len(AA seq)
PDB file >>>559_XYLT1_ABR	ENST00000261381	ENST00000302538	XYLT1	chr16	17352845	ABR	chr17	1028702	MRGARGRPGACRGPRASLAGRAPKMVAAPCARRLARRSHSALLAALTVLLLQTLVVWNFSSLDSGAGERRGGAAVGGGEQPPPAPAPRRE RRDLPAEPAAARGGGGGGGGGGGGRGPQARARGGGPGEPRGQQPASRGALPARALDPHPSPLITLETQDGYFSHRPKEKVRTDSNNENSV PKDFENVDNSNFAPRTQKQKHQPELAKKPPSRQKELLKRKLEQQEKGKGHTFPGKGPGEVLPPGDRAAANSSHGKDVSRPPHARKTGGSS PETKYDQPPKCDISGKEAISALSRAKSKHCRQEIGETYCRHKLGLLMPEKVTRFCPLEDFSYGTDEYDGEGNEEQKGPPEGSETMPYIDE SPTMSPQLSARSQGGGDGVSPTPPEGLAPGVEAGKGLEMRKLVLSGFLASEEIYINQLEALLLPMKPLKATATTSQPVLTIQQIETIFYK IQDIYEIHKEFYDNLCPKVQQWDSQVTMGHLFQKLASQLGVYKAFVDNYKVALETAEKCSQSNNQFQKISEELKVKGPKDSKDSHTSVTM EALLYKPIDRVTRSTLVLHDLLKHTPVDHPDYPLLQDALRISQNFLSSINEDIDPRRTAVTTPKGETRQLVKDGFLVEVSESSRKLRHVF LFTDVLLCAKLKKTSAGKHQQYDCKWYIPLADLVFPSPEESEASPQVHPFPDHELEDMKMKISALKSEIQKEKANKGQSRAIERLKKKMF ENEFLLLLNSPTIPFRIHNRNGKSYLFLLSSDYERSEWREAIQKLQKKDLQAFVLSSVELQVLTGSCFKLRTVHNIPVTSNKDDDESPGL YGFLHVIVHSAKGFKQSANLYCTLEVDSFGYFVSKAKTRVFRDTAEPKWDEEFEIELEGSQSLRILCYEKCYDKTKVNKDNNEIVDKIMG KGQIQLDPQTVETKNWHTDVIEMNGIKVEFSMKFTSRDMSLKRTPSKKQTGVFGVKISVVTKRERSKVPYIVRQCVEEVEKRGIEEVGIY RISGVATDIQALKAVFDANNKDILLMLSDMDINAIAGTLKLYFRELPEPLLTDRLYPAFMEGIALSDPAAKENCMMHLLRSLPDPNLITF	1167
3D view using mol* of 559_XYLT1_ABR

PDB file >>>TKFP_953_XYLT1_ABR	ENST00000261381	ENST00000302538	XYLT1	chr16	17352845	ABR	chr17	1028702	MRGARGRPGACRGPRASLAGRAPKMVAAPCARRLARRSHSALLAALTVLLLQTLVVWNFSSLDSGAGERRGGAAVGGGEQPPPAPAPRRE RRDLPAEPAAARGGGGGGGGGGGGRGPQARARGGGPGEPRGQQPASRGALPARALDPHPSPLITLETQDGYFSHRPKEKVRTDSNNENSV PKDFENVDNSNFAPRTQKQKHQPELAKKPPSRQKELLKRKLEQQEKGKGHTFPGKGPGEVLPPGDRAAANSSHGKDVSRPPHARKTGGSS PETKYDQPPKCDISGKEAISALSRAKSKHCRQEIGETYCRHKLGLLMPEKVTRFCPLEDFSYGTDEYDGEGNEEQKGPPEGSETMPYIDE SPTMSPQLSARSQGGGDGVSPTPPEGLAPGVEAGKGLEMRKLVLSGFLASEEIYINQLEALLLPMKPLKATATTSQPVLTIQQIETIFYK IQDIYEIHKEFYDNLCPKVQQWDSQVTMGHLFQKLASQLGVYKAFVDNYKVALETAEKCSQSNNQFQKISEELKVKGPKDSKDSHTSVTM EALLYKPIDRVTRSTLVLHDLLKHTPVDHPDYPLLQDALRISQNFLSSINEDIDPRRTAVTTPKGETRQLVKDGFLVEVSESSRKLRHVF LFTDVLLCAKLKKTSAGKHQQYDCKWYIPLADLVFPSPEESEASPQVHPFPDHELEDMKMKISALKSEIQKEKANKGQSRAIERLKKKMF ENEFLLLLNSPTIPFRIHNRNGKSYLFLLSSDYERSEWREAIQKLQKKDLQAFVLSSVELQVLTGSCFKLRTVHNIPVTSNKDDDESPGL YGFLHVIVHSAKGFKQSANLYCTLEVDSFGYFVSKAKTRVFRDTAEPKWDEEFEIELEGSQSLRILCYEKCYDKTKVNKDNNEIVDKIMG KGQIQLDPQTVETKNWHTDVIEMNGIKVEFSMKFTSRDMSLKRTPSKKQTGVFGVKISVVTKRERSKVPYIVRQCVEEVEKRGIEEVGIY RISGVATDIQALKAVFDANNKDILLMLSDMDINAIAGTLKLYFRELPEPLLTDRLYPAFMEGIALSDPAAKENCMMHLLRSLPDPNLITF	1167_XYLT1_ABR

Top

Comparison of Fusion Protein Isoforms

Superimpose the 3D Structures Among All Fusion Protein Isoforms
* Download the pdb file and open it from the molstar online viewer.

Comparison of the Secondary Structures of Fusion Protein Isoforms

Top

Comparison of Fusion Protein Sequences/Structures with Known Sequences/Structures from PDB

XYLT1_ABR does not have any known PDB structures.

Top

pLDDT score distribution

all_data/KinaseFusionDB_T_Results/KinaseFusionDB_T_ViolinPlots/559_XYLT1_ABR.png

pLDDT score distribution of the predicted fusion protein structures from AlphaFold2
* AlphaFold produces a per-residue confidence score (pLDDT) between 0 and 100.
* The blue color at the bottom marks the best active site residues.

559_XYLT1_ABR.png

Top

Potential Active Site Information

The potential binding sites of these fusion proteins were identified using SiteMap, a module of the Schrodinger suite.

Kinase Fusion AA seq ID in KinaseFusionDB

Site score

Size

Dscore

Volume

Exposure

Enclosure

Contact

Phobic

Philic

Balance

Don/Acc

Residues

Top

Ramachandran Plot of Kinase Fusion Protein Structure

Ramachandran plot of the torsional angles - phi (φ)and psi (ψ) - of the residues (amino acids) contained in this fusion protein peptide.

559_XYLT1_ABR_ramachandran.png

Top

Virtual Screening Results

Distribution of the average docking score across all approved kinase inhibitors.
Distribution of the number of occurrence across all approved kinase inhibitors.

5'-kinase fusion protein case

3'-kinase fusion protein case

Top

Drug information from DrugBank of the top 20 interacting small molecules.
* The detailed information of individual kinase inhibitors are available in the download page.

Fusion gene name info	Drug	Docking score	Glide g score	Glide energy
559_XYLT1_ABR-DOCK_HTVS_1-001	Midostaurin	-6.8743	-6.8743	-43.953
559_XYLT1_ABR-DOCK_HTVS_1-001	Crizotinib	-6.43321	-6.9291100000000005	-47.7907
559_XYLT1_ABR-DOCK_HTVS_1-001	Crizotinib	-6.43321	-6.9291100000000005	-47.7907
559_XYLT1_ABR-DOCK_HTVS_1-001	Selpercatinib	-6.40056	-6.4310599999999996	-51.1689
559_XYLT1_ABR-DOCK_HTVS_1-001	Selpercatinib	-6.40056	-6.4310599999999996	-51.1689
559_XYLT1_ABR-DOCK_HTVS_1-001	Netarsudil	-6.0707699999999996	-6.081869999999999	-50.7951
559_XYLT1_ABR-DOCK_HTVS_1-001	Netarsudil	-6.0707699999999996	-6.081869999999999	-50.7951
559_XYLT1_ABR-DOCK_HTVS_1-001	Tofacitinib	-6.0681199999999995	-6.079619999999999	-31.2328
559_XYLT1_ABR-DOCK_HTVS_1-001	Tofacitinib	-6.0681199999999995	-6.079619999999999	-31.2328
559_XYLT1_ABR-DOCK_HTVS_1-001	Osimertinib	-5.91547	-5.92317	-52.9908
559_XYLT1_ABR-DOCK_HTVS_1-001	Zanubrutinib	-5.81727	-5.81727	-48.8643
559_XYLT1_ABR-DOCK_HTVS_1-001	Trametinib	-5.7374	-5.7374	-44.1976
559_XYLT1_ABR-DOCK_HTVS_1-001	Larotrectinib	-5.6721699999999995	-5.6721699999999995	-38.0016
559_XYLT1_ABR-DOCK_HTVS_1-001	Selpercatinib	-5.63282	-5.66332	-49.2319
559_XYLT1_ABR-DOCK_HTVS_1-001	Crizotinib	-5.612419999999999	-5.94862	-46.0914
559_XYLT1_ABR-DOCK_HTVS_1-001	Crizotinib	-5.612419999999999	-5.94862	-46.0914
559_XYLT1_ABR-DOCK_HTVS_1-001	Lapatinib	-5.57251	-5.66131	-56.3693
559_XYLT1_ABR-DOCK_HTVS_1-001	Temsirolimus	-5.53216	-5.53356	-53.495
559_XYLT1_ABR-DOCK_HTVS_1-001	Lapatinib	-5.5173	-5.6061	-57.1509
559_XYLT1_ABR-DOCK_HTVS_1-001	Pazopanib	-5.513380000000001	-5.5202800000000005	-43.1229

Top

Kinase-Substrate Information of XYLT1_ABR

Phosphorylation target of the kinase
(phosphosite, 03-17-2024)

Kinase

Kinase UniProt Acc

Kinase species

Substrate

Substrate UniProt Acc

Substrate phosphorylated residues

Substrate phosphorylated sites (+/-7AA)

Domain

Biological Network Integration of This Kinase and Substrates
(GeneMANIA website)

Enriched GO biological processes of the phosphorylation target genes of the kinase

Kinase

GOID

GO term

P.adjust

Top

Related Drugs to XYLT1_ABR

Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Drug

Source

PMID

Distribution of the number of studies mentioning XYLT1-ABR and kinase inhibitors the PubMed Abstract (04-01-2024)

Fusion gene - drug pair 1

Fusion gene - drug pair 2

PMID

Publication date

DOI

Study title

Top

Related Diseases to XYLT1_ABR

Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)

Hgene

Tgene

Disease

Source

PMID

Related diseases from the literature mentioned this fusion gene and drug.
(PubMed, 04-01-2024)

MeSH ID

MeSH term

Diseases associated with fusion partners.
(DisGeNet 4.0)

Partner

Gene

Disease ID

Disease name

# pubmeds

Source

Top

Clinical Trials of the Found Drugs/Small Molecules

Statistics of the Clinical Trials of the Found Kinase Inibitors from clinicaltrials.gov (06-17-2024)

Clinical Trials from clinicaltrials.gov (06-17-2024)

Fusion Gene

Kinase Inhibitor

NCT ID

Study Status

Phases

Disease

# Enrolment

Date